Seven years after regaining rights to BG00011 (STX-100), Biogen terminated its Phase II trial of the mAb for idiopathic pulmonary fibrosis (IPF) due to safety concerns. Biogen Inc. (NASDAQ:BIIB) had licensed the humanized mAb against...

Indalo Therapeutics Inc. is targeting the root causes in fibrosis by antagonizing multiple integrins simultaneously to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling. Indalo President and CEO Robert...

In its 3Q17 earnings presentation, Biogen Inc. (NASDAQ:BIIB) said BG00011 (STX-100) achieved "proof of biology" in a Phase IIa trial by showing "substantial" downregulation of the transforming growth factor (TGF) beta pathway as measured by...

Patients at FDA 's recent workshop on idiopathic pulmonary fibrosis said they want treatments that can halt or reverse the progression of fibrosis and - just as importantly - improve quality of life. But they will have...

Patients at FDA 's recent workshop on idiopathic pulmonary fibrosis said they want treatments that can halt or reverse the progression of fibrosis and - just as importantly - improve quality of life. But they will have...

InterMune Inc. 's third Phase III trial transformed it from a forgotten company with $70.3 million in 2013 sales of one Orphan product to a takeout play worth $8.3 billion to Roche . The question now...

An undisclosed company has picked up an integrin-targeting antibody from the University of California, San Francisco that could address the underlying pathology in chronic obstructive pulmonary disease by improving airway remodeling via suppressing transforming growth...

Fibrosis has long been associated with the activation of transforming growth factor-b by integrin, but the mechanism underlying the process in vivo was not known. Now, an international team has shown that the myofibroblast-expressed integrin...

Biogen Idec disclosed in its 2Q12 earnings that in July it began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate weekly subcutaneous STX-100 for 8 weeks in 32 IPF patients. The trial includes 4...

A U.S. and South Korean research team has identified the molecular target of halofuginone, a small molecule antifibrotic and anti-inflammatory compound. 1 The findings could help guide the design of next-generation halofuginone analogs with improved...